Arena Pharmaceuticals to Present at CIBC World Markets 16th Annual Healthcare Conference
SAN DIEGO, Nov 02, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA) announced today that it will present at the CIBC World Markets
16th Annual Healthcare Conference on Tuesday, November 8, 2005, at 3:30 p.m.
Eastern Time (12:30 p.m. Pacific Time) at the Waldorf-Astoria in New York
City. Jack Lief, Arena's President and Chief Executive Officer, will provide
a corporate update and an overview of Arena and its clinical development and
A live audio webcast of the presentation will be available under the
investor relations section of Arena's website at www.arenapharm.com. Replays
of the presentation will be available for 30 days following the event. Please
connect to Arena's website several minutes prior to the start of the
conference call to ensure adequate time for any software download that may be
About Arena Pharmaceuticals
Arena is a clinical-stage biopharmaceutical company focusing on the
discovery, development and commercialization of small molecule drugs in four
major therapeutic areas: metabolic, cardiovascular, inflammatory and central
nervous system diseases. Arena is developing a broad pipeline of compounds
that act on an important class of drug targets called G protein-coupled
receptors, or GPCRs, using its knowledge of GPCRs and its technologies,
including CART (Constitutively Activated Receptor Technology) and
Melanophore. Arena has three internally discovered, clinical-stage product
candidates. Arena's most advanced clinical compound, APD356, a selective
5-HT2C serotonin receptor agonist for the treatment of obesity, is in
Phase 2b. Arena's lead product candidate for the treatment of insomnia,
APD125, a compound with a novel mechanism of action (a selective 5-HT2A
receptor inverse agonist), is scheduled to begin a Phase 2 clinical trial by
the end of 2005. As part of Arena's partnership with Merck & Co., Inc., an
Arena product candidate for the treatment of atherosclerosis and related
disorders is in a Phase 1 clinical trial. Arena also has an active
collaboration with Ortho-McNeil, Inc., a Johnson & Johnson company, for the
treatment of type 2 diabetes.
Arena Pharmaceuticals® and Arena® are registered service marks of the
company. CART is an unregistered service mark of the company.
Certain statements in this press release are forward-looking statements
that involve a number of risks and uncertainties. Such forward-looking
statements include statements about the expected timing of Arena's Phase 2
clinical trial of APD125 and other statements about Arena's strategy,
technologies, preclinical and clinical programs, and ability to develop
compounds and commercialize drugs. For such statements, Arena claims the
protection of the Private Securities Litigation Reform Act of 1995. Actual
events or results may differ materially from Arena's expectations. Factors
that could cause actual results to differ materially from the forward-looking
statements include, but are not limited to, the results of Arena's clinical
trials, the results of preclinical studies or clinical trials may not be
predictive of future results, Arena's ability to partner APD356, APD125 or
other of its compounds or programs, the timing, success and cost of Arena's
research, out-licensing endeavors and clinical trials, Arena's ability to
obtain additional financing, Arena's ability to obtain and defend its patents,
Arena's patent protection, and the timing and receipt of payments and fees, if
any, from Arena's collaborators, including Ortho-McNeil and Merck. Additional
factors that could cause actual results to differ materially from those stated
or implied by Arena's forward-looking statements are disclosed in Arena's
filings with the Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this release. Arena
disclaims any intent or obligation to update these forward-looking statements,
other than as may be required under applicable law.
Contacts: Jack Lief Media:
President and CEO Carin Canale
Atkins + Associates
David Walsey (858) 527-3498
Director, Corporate Communications
Arena Pharmaceuticals, Inc.
(858) 453-7200, ext. 1682
SOURCE Arena Pharmaceuticals, Inc.
Jack Lief, President and CEO, or David Walsey, Director, Corporate Communications,
both of Arena Pharmaceuticals, Inc., +1-858-453-7200, ext. 1682; or Carin Canale of
Atkins + Associates, +1-858-527-3498, for Arena Pharmaceuticals, Inc.
You are now leaving arenapharm.com and being directed to a site not maintained by Arena. Arena is not responsible for content or privacy policies on other sites.